Survodutide

$115.48

✅ 99% Purity – Third-Party Tested

🚚 Free U.S. Shipping on Orders $100+

🇺🇸 Proudly Made in the USA

⚡ Fast & Reliable Shipping

🔒 Secure Checkout Guaranteed

SKU: N/A Category:

Overview of Survodutide 10mg

Survodutide is a synthetic peptide based on dual agonist. Survodutide is being studied in clinical and preclinical research for metabolic dysfunction-associated steatotic liver disease (MASLD).

It is also being investigated for obesity and metabolic regulatory pathways in different experimental research studies.

Chemical and Molecular Properties

Pubchem CID 168429725
Molecular Formula C192H289N47O61
Synonyms Survodutide

2805997-46-8

GTPL13383

EX-A7878

BI456906

Molecular Weight 4232 g/mol
IUPAC 18-[[4-[[2-[[(2R)-1-[[2-[[(2R)-1-[[2-[[2-[[(5R)-5-[[(2S,3S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[1-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]cyclobutanecarbonyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]………
CAS 2805997-46-8
Chemical Structure Depiction
Environmental precautions Do not allow water to enter sewers/ surface, or groundwater.
Conditions for safe storage Keep the container tightly sealed in a cool, well-ventilated area. Keep away from direct sunlight and sources of ignition
SOLUBILITY SOLUBILITY PBS (pH 7.2): Soluble: ≥10 mg/ml
Precautions for safe handling Avoid inhalation, contact with eyes, and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.
FDA approval status Not FDA approved

Surovitide Mechanism of Action

Survodutide works by activating two metabolic hormone receptors at the same time in research models. These two receptors are

  • GLP-1 receptor (GLP-1R)
  • Glucagon receptor (GCGR)

GLP-1 receptor activation is known to regulate appetite in approved therapies, and Survodutide is being studied to determine whether similar mechanisms occur.

Researchers are evaluating whether Survodutide influences gastric emptying and glucose regulation in clinical research.

On the other hand, the Glucagon receptor (GCGR) activation primarily occurs in the liver of preclinical models, studied for its role in:

  • Increasing energy expenditure mechanisms in experimental preclinical research
  • Promoting lipolysis and fat oxidation
  • Reducing hepatic fat accumulation

Survodutide vs GLP-1 Receptor Agonists

Survodutide differs from traditional GLP-1 receptor agonists because it is designed to activate both GLP-1 and glucagon receptors.

Aspects Survodutide Traditional GLP-1 Agonist
Receptor Activity GLP-1R + GCGR GLP-1R only
Metabolic Research Focus Appetite + Energy Expenditure Pathways Primarily appetite-related pathways

Handling and Storage of Survodutide

Handling and storing Survodutide are important for long-term research use. Here are the guidelines to follow:

  • Researchers have suggested that Survodutide powder can be stored at -80°C for long-term and -20°C for short-term.
  • Use it carefully in lab settings.
  • Keep vials tightly sealed and clearly labelled with concentration and date of reconstitution.
  • Use sterile containers to prevent contamination.
  • Keep it away from moisture and humidity.

Research Application of Survodutide

Survodutide is being investigated by various researchers in labs for its following potential applications.

  • Researchers study this compound to learn its role in glucose homeostasis pathways.
  • Survodutide is being investigated for appetite-regulating pathways in preclinical experimental models.
  • A few researchers may explore its effects on gastric emptying and gastrointestinal motility in an experimental model.
  • It might be evaluated for cardiovascular and metabolic outcomes in preclinical studies.

Why Buy Survodutide Online from Purerawz?

Purerawz is an online shop that gives researchers of all levels the premium quality Survodutide for research purposes.

We offer first- and third-party tested Survodutide with a proper Certificate of Analysis. In addition, we have a hassle-free shipping process and easy, secure transaction options.

Disclaimer

This information is for educational purposes only and not medical advice. Products are for research use only. Research must follow IRB or IACUC guidelines. Verify information independently before purchasing. By ordering, you agree to our Terms and Conditions. If you are not 100% satisfied with the product you received, please contact us at support@purerawz.co

ATTENTION: All our products are for LABORATORY AND RESEARCH PURPOSES ONLY, not for veterinary or human use

 

Reference Links

  • le Roux, C. W., Wharton, S., Bozkurt, B., Platz, E., Bleckert, G., Ajaz Hussain, S., Brueckmann, M., Startseva, E., Kloer, I. M., & Kaplan, L. M. (2025). Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial ( SYNCHRONIZE TM-1). Diabetes, Obesity, and Metabolism. https://doi.org/10.1111/dom.70196
  • le Roux, C. W., Wharton, S., Bozkurt, B., Platz, E., Bleckert, G., Ajaz Hussain, S., Brueckmann, M., Startseva, E., Kloer, I. M., & Kaplan, L. M. (2025). Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial ( SYNCHRONIZE TM-1). Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70196
  • Kosiborod, M. N., Platz, E., Wharton, S., le Roux, C. W., Brueckmann, M., Ajaz Hussain, S., Unseld, A., Startseva, E., & Kaplan, L. M. (2024). Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial. JACC: Heart Failure, 12(12), 2101-2109. https://doi.org/10.1016/j.jchf.2024.09.004
Strength

10mg